Qsemble Capital Management LP Sells 1,154 Shares of Masimo Co. (NASDAQ:MASI)

Qsemble Capital Management LP trimmed its position in shares of Masimo Co. (NASDAQ:MASI) by 41.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,617 shares of the medical equipment provider’s stock after selling 1,154 shares during the quarter. Qsemble Capital Management LP’s holdings in Masimo were worth $216,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. NBC Securities Inc. grew its stake in shares of Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 73 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Masimo by 75.0% during the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 111 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in shares of Masimo by 133.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 200 shares during the last quarter. HHM Wealth Advisors LLC grew its stake in shares of Masimo by 25.0% during the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after purchasing an additional 125 shares during the last quarter. Finally, Lazard Asset Management LLC grew its stake in shares of Masimo by 5,730.0% during the first quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 573 shares during the last quarter. 85.96% of the stock is owned by institutional investors.

Masimo Trading Down 0.8 %

MASI opened at $170.89 on Thursday. The firm’s fifty day moving average is $147.03 and its two-hundred day moving average is $129.03. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The firm has a market cap of $9.15 billion, a PE ratio of 117.86 and a beta of 0.97. Masimo Co. has a twelve month low of $91.60 and a twelve month high of $178.27.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.14. The company had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period last year, the business posted $0.63 earnings per share. Equities research analysts anticipate that Masimo Co. will post 4.04 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Piper Sandler increased their price target on shares of Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Raymond James raised shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price target on the stock in a research note on Wednesday, November 6th. Stifel Nicolaus restated a “buy” rating and issued a $190.00 price objective (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Wells Fargo & Company increased their price objective on shares of Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Masimo presently has a consensus rating of “Moderate Buy” and an average target price of $167.00.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.